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ABSTRACT
Introduction: Skin and soft tissue infections
involve microbial invasion of the skin and
underlying soft tissues and are estimated to
affect 7–10% of hospitalized patients
worldwide. Nadifloxacin, a topical
fluoroquinolone, has been shown to be
effective against aerobic Gram-negative, Gram-
positive (including MRSA and coagulase-
negative staphylococci), and anaerobic
bacteria. However, there is paucity of data
comparing efficacy and safety of 1%
nadifloxacin with other anti-bacterials for skin
infections in Indian patients.
Methods: This article presents the results of one
post-marketing surveillance (PMS) and three
randomized, open, non-blinded, multi-centric
clinical studies that compared nadifloxacin with
mupirocin and framycetin, and nadifloxacin
with fusidic acid. Patients in India, aged from 1
to 65 years old, suffering from mild to moderate
bacterial skin infections including impetigo,
secondarily infected wounds, folliculitis,
infected atopic dermatitis, and furunculosis
were randomly allocated to three treatment
groups within the studies. Efficacy was assessed
by the evaluation of symptoms of erythema,
exudation, swelling, pruritus, crusting, pain and
tenderness in all the studies.
Results: A total of 272 subjects were enrolled in
the study and subjects were randomly assigned
to one of the three treatment groups; 92 in the
nadifloxacin group, 90 in the mupirocin group,
and 90 in the framycetin group. A significant
reduction in the mean scores for bacterial
infection symptoms in the nadifloxacin groups
was observed when compared to mupirocin,
framycetin and fusidic acid groups. Both
physician and patients rated nadifloxacin as
excellent (complete remission of symptoms) on
a 4-point scale in the studies. No adverse events
(AEs) were reported in the clinical studies. In
the PMS, only two patients (of 329, 0.6%)
reported AEs including burning and itching,
one in each patient that had resolved at the
time of reporting.
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Conclusion: Nadifloxacin, a fluoroquinolone, is
a new alternative topical agent in the treatment
of bacterial skin infection with minimal AEs.




Skin and soft tissue infections (SSTIs) involve
microbial invasion of the skin and underlying
soft tissues and are estimated to affect 7–10% of
hospitalized patients worldwide. The estimated
incidence rate of SSTIs is 24.6 per 1,000 person-
years [1]. A study from India reported that the
prevalence of infections caused by methicillin-
resistant Staphylococcus aureus (MRSA) was 42%
in 2008 and 40% in 2009 [2]. Common
superficial bacterial infections of the skin
include impetigo, folliculitis, furunculosis,
cellulitis, acne and others. Topical antibiotics
like mupirocin and fusidic acid are the common
topical anti-bacterials used for these bacterial
skin infections [3–5].
Nadifloxacin, a topical fluoroquinolone, acts
by inhibiting the configuration of negative
supercoiling of bacterial DNA, catalyzed by
DNA gyrase. DNA gyrase is an enzyme present
in every bacterium and is essential for DNA
replication, transcription, and recombination
[6]. Nadifloxacin has been shown to be effective
against aerobic Gram-negative, Gram-positive
(including MRSA and coagulase-negative
staphylococci), and anaerobic bacteria [7–10].
It is approved for use in acne treatment and skin
infections in Japan [11].
Nadifloxacin has shown good safety and
efficacy against several bacteria. Previous
in vitro studies for bacterial skin infections
found nadifloxacin to be highly potent against
aerobic and anaerobic bacteria such as
Propionibacterium species, Streptococcus species,
and Staphylococcus species [10, 12, 13].
Nadifloxacin has been in use for treatment of
acne vulgaris for the past two decades and has
shown good safety and efficacy profiles [11, 14–
16]. However, nadifloxacin has not been
frequently used to treat bacterial infections of
the skin.
A phase II trial of nadifloxacin 1% cream in
101 patients with impetigo, secondarily infected
wounds, folliculitis, sycosis vulgaris, and
impetiginized dermatitis reported a significant
reduction in the degree of erythema, exudation,
swelling, pain, pruritus, erosion, crusts and
scaling, and eradication of causative bacteria.
The adverse events (AEs) reported were
infrequent with only three patients
complaining of erythema, itching, and
inflammatory swelling on day 4 and day 7 of
the study. No serious AEs were reported [17, 18].
There is a paucity of data comparing efficacy
and safety of 1% nadifloxacin with other anti-
bacterials for skin infections in Indian patients.
This article presents the results of four studies (3
randomized controlled trials and 1 post-
marketing surveillance) conducted on an
Indian population to investigate the efficacy
and safety of nadifloxacin (NadoxinTM,
Wockhardt Ltd., Mumbai, India) in the
treatment of mild to moderate bacterial skin
infections when compared with other anti-




Indian subjects, aged 1–65 years old, suffering
from mild to moderate bacterial skin infections
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that included impetigo, secondarily infected
wounds, folliculitis, infected atopic dermatitis,
furunculosis and those willing to sign informed
consent were enrolled in the study. Patients
with a history of hypersensitivity to
aminoglycosides, quinolones, and mupirocin,
patients on topical anti-bacterial treatment
during 1 week prior to study and those
suffering from any other severe bacterial skin
infections were not enrolled in the study.
Patients with a history of chronic alcohol/drug
abuse, those on another investigational drug
during the previous 12 weeks, presence of severe
concomitant diseases, patients receiving any
systemic antibiotics during 2 weeks prior to the
study and pregnant women or nursing mothers
were excluded from the study.
Compliance with Ethics Guidelines
All procedures followed were in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in 2000
and 2008. Informed consent was obtained from
all patients for being included in the studies.
Study Design
The three clinical studies were comparative,
open, multi-centric, and randomized with study
duration of 14 days and the other was a phase
IV study. Eligible subjects in study 1 were
randomly allocated to either of the three
treatment groups; the nadifloxacin group, the
mupirocin group, or the framycetin group.
Subjects in study 2 and study 3 were randomly
allocated to receive either nadifloxacin or
fusidic acid (Fig. 1). All the subjects were
followed up at day 3, day 7 and day 14.
The phase IV study was an observational,
open-label, non-comparative, multi-centric,
post-marketing surveillance (PMS) conducted
across 125 centers in India. Duration for the
study was 7 days and extended to 14 days for
those subjects who did not show any
improvement in the initial 7 days.
Assessment
The primary outcome variables in all the three
studies were improvement in scores (on a scale
of 0—absent to 3—severe) of erythema,
crusting, exudation, swelling, pruritus, pain
and tenderness. In study 1, the number of
lesions and size of wound scores were also
assessed.
The secondary outcome variable included
global assessment by the patient and the




tolerability was assessed based on AEs
experienced by the patients during the
treatment period.
Dosage Schedule
In study 1, 1% nadifloxacin cream, 2%
mupirocin or 1% framycetin ointment were
given twice daily, once in the morning and
once in the evening for at least 7 days and
maximum up to 14 days.
In study 2 and study 3, 1% nadifloxacin or
2% fusidic acid were given twice daily, once in
the morning and once in the evening for at least
7 days and maximum up to 14 days.
In the PMS study, 1% nadifloxacin cream
was used to treat enrolled patients, and the
dosage schedule varied from patient to patient.
Majority (n - 101) of the patients received the
study drug once in the morning and once in the
evening for a period of 1 week.
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Statistical Analysis
All the parameters were measured on a
continuous scale, expressed as mean ± SD
and compared using Student’s t test. All the
parameters were subjected to Chi-Squared
test. Wilcoxon signed-rank and Chi-squared





A total of 272 subjects were enrolled in the
study and all of them completed the study.
Subjects were randomly assigned to one of three
treatment groups; 92 in the nadifloxacin group,
90 in the mupirocin group, and 90 in the
framycetin group. The demographic details of
the patients are presented in Table 1. Only two
patients from nadifloxacin group had a previous
history of other disease, whereas none of the
patients from mupirocin group and framycetin
group had any disease history. History of
previous drug intake was reported in 33
(35.9%) patients from nadifloxacin group, 37
(41.1%) from mupirocin group and 37 (41.1%)
from framycetin group.
Study 2
This study enrolled 49 patients, aged 1–65 years
old, of which 38 patients (nadifloxacin group—
22, fusidic acid group—16) completed the
study. The patient’s profiles in both the groups
were broadly similar (Table 1) with a majority of
them suffering from impetigo, pyoderma or
boils, periporitis and miscellaneous secondary
infections.
Fig. 1 Study design and patient disposition
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Study 3
Of 49 patients (1–60 years old) enrolled in the
study, 43 patients (nadifloxacin group—24,
fusidic acid group—19) completed the study.
The majority of the patients were men
(nadifloxacin group—67%, fusidic acid
group—68%). The mean age of the patients in
the nadifloxacin group and the fusidic acid
group was 15.2 ± 15.7 years and
9.0 ± 13.1 years, respectively (Table 1).
Phase IV Study
Of the 329 patients enrolled in 125 centers
across India, 323 patients completed the study.
The majority of the patients were men (61%),
317 (98.4%) patients were aged 60 years or less
and 6 (1.9%) were more than 60 years old with a





The clinical cure rates were significantly higher
in the nadifloxacin and mupirocin groups on
day 3 (70.7% and 72.2%, respectively) and day 7
(97.8% and 97.8%, respectively) as compared
with framycetin group (46.6% on day 3 and
0.8% on day 7; p\0.05) (Fig. 2). A significant
reduction was reported in the mean scores for
pain and tenderness on days 3, 7 and 14 as
compared with baseline scores in all the three
treatment groups (p\0.05). The reduction in
mean score was similar in the nadifloxacin and
mupirocin groups and was significantly greater
than that in the framycetin group (p\0.05).
Similar results were found for other parameters
like the number of lesions, size of lesions,
erythema, crusting, exudation, swelling and
pruritus. Figure 3a depicts the improvement in
clinical parameters with nadifloxacin and
mupirocin.
Secondary Parameters
Global Assessment of the Treatment by
Patients Overall, 44 (47.8%) patients rated
nadifloxacin as excellent (complete remission
of symptoms) compared to only 11 (12.2%)
from the mupirocin group and 7 (7.8%) from
the framycetin group, whereas 46 (50%) from
the nadifloxacin group and 58 (64.4%) from the
mupirocin group rated the therapy as good
(acceptable remission of symptoms). Eight
(8.9%) patients from the framycetin group
rated it as poor (unchanged/aggravated)
compared to only 3 (3.3%) from the
mupirocin group and zero patients from the
nadifloxacin group (Fig. 4a).
Global Assessment of the Treatment by
Physician In 43 (46.7%) patients, the
investigator rated nadifloxacin as excellent
(complete remission of symptoms), whereas in
only 19 (11.1%) patients from the mupirocin
group and 9 (10%) patients from the framycetin
group, the investigator rated nadifloxacin as
excellent (complete remission of symptoms). In
44 patients (47.8%) from the nadifloxacin
group and 56 (62.2%) from the mupirocin
group, the investigator rated the therapy as
good (acceptable remission of symptoms). In 14
patients (15.6%) from the framycetin group, the
investigator rated it as poor (unchanged/
aggravated) against zero patients from the
nadifloxacin and mupirocin groups (Fig. 4b).
Study 2
Primary Parameters
The mean severity scores for almost all the
signs/symptoms like erythema, exudation,
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swelling, pruritus, pain and tenderness were
significantly reduced on day 3 and day 7,
compared with the baseline in both the
treatment groups (p\0.05). On day 3, the
mean severity scores for signs/symptoms like
crusting, exudation, swelling and pruritus were
significantly reduced in the nadifloxacin group
when compared to the fusidic acid group
(p\0.05). The majority of the evaluable
symptoms were relieved in more patients in
the nadifloxacin group on day 3 compared to
the number of patients in the fusidic acid group
(Fig. 3b). However, the majority of the evaluable
symptoms were relieved on day 7 in both the
treatment groups. The lesions were healed in
77% and 95% of patients on day 3 and day 7,
respectively, in the nadifloxacin group
compared to 19% and 81% of patients in the
fusidic acid group (Fig. 2).
Secondary Parameters
Global Assessment by Patients All 22 (100%)
patients in the nadifloxacin group rated the
overall response to the application of the study
cream as excellent (complete remission of
symptoms) compared to only 6 patients
(37.5%) from the fusidic acid group. The
remaining 10 (62.5%) patients in the fusidic
acid group rated the therapy as good (acceptable
remission of symptoms) due to inadequate
response on day 3 (Fig. 4a).
Global Assessment by Physician The
physician rated the overall response to the
application of the study cream as excellent
(complete remission of symptoms) in all 22
patients (100%) in the nadifloxacin group
compared to 4 patients (25%) from the fusidic
acid group. The physicians rated the overall
response to fusidic acid as good (acceptable
remission of symptoms) and fair (slight/
incomplete remission of symptoms) in 5
(31.3%) and 7 (43.8%) patients, respectively,
due to an inadequate response and persistence
of the clinical symptoms on day 3 (Fig. 4b).
Study 3
Primary Parameters
The mean severity scores for almost all the signs
and symptoms like erythema, exudation,
swelling, pruritus, pain and tenderness were
significantly reduced on day 3, day 7 and day 14
(except tenderness in the fusidic acid group) in
Fig. 2 Clinical cure rate (%) in study 1 and study 2
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both groups. At day 7, the mean severity score
for pruritus was significantly reduced in the
nadifloxacin group and the fusidic acid group
(p\0.05). There was no statistically significant
difference for mean severity scores for other
symptoms and signs between two groups
(Fig. 3c). The lesions were healed in 42% and
83% of patients on day 3 and day 7,
respectively, in the nadifloxacin group
compared to 21% and 63% of patients in the
Fig. 3 a Improvement in mean score for evaluable symp-
toms at day 3, day 7 and day 14 in study 1. b Improvement
in mean score for evaluable symptoms at day 3 and day 7 in
study 2. c Improvement in mean score for evaluable
symptoms at day 3, day 7and day 14 in study 3
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fusidic acid group. Thus, nadifloxacin resulted
in healing of bacterial skin infection lesions in a
higher number of patients when compared to
the fusidic acid group.
Secondary Parameters
Global Assessment by Patient In the
nadifloxacin group, 11 (45.8%) patients rated
the overall response to the application of the
study cream as excellent (complete remission
of symptoms) compared to only 3 (15.8%)
patients from the fusidic acid group. The
remaining 13 (54.2%) patients from the
nadifloxacin group rated the therapy as good
(acceptable remission of symptoms), whereas
12 (63.2%) and 4 (21.1%) patients from the
fusidic acid group rated the therapy as good
(acceptable remission of symptoms) and fair
(slight/incomplete remission of symptoms),
respectively (Fig. 4a).
Global Assessment by Investigator The
investigator rated the overall response to the
application of the study cream on a 4-point
scale as excellent (complete remission of
symptoms) in 11 (45.8%) patients in the
nadifloxacin group compared to 4 (20.5%)
patients) in the fusidic acid group. The
remaining 12 (50%) and 1 (4.2%) patients
from the nadifloxacin group received good
(acceptable remission of symptoms) and fair
(slight/incomplete remission of symptoms)
response ratings from the investigator,
compared with 11 (57.9%) and 4 (21.1%)




Clinical efficacy of nadifloxacin was evaluated
by assessing the improvement in primary
parameters including clinical experience of the
lesions in term of erythema, exudation,
swelling, pruritus, crusting, pain, tenderness
before study, at day 7 and day 14 (Table 2).
Fig. 3 continued
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Secondary Parameters
Global Assessment by Patients The efficacy of
nadifloxacin in treatment of bacterial skin
infections was rated by patients as excellent
(complete remission of symptoms) for 221
(67.2%) patients, good (acceptable remission
of symptoms) in 39 (11.9%) patients, fair
(slight/incomplete remission of symptoms) in
66 (20.1%) patients and poor (unchanged/
aggravated) in 3 (0.9%) patients (Fig. 4c).
Fig. 4 a Global assessment of nadiﬂoxacin and other
comparator drugs by patients in study 1, study 2 and study
3. b Global assessment of patient by investigator in study 1,
study 2 and study 3 treated with nadiﬂoxacin and
comparator drugs. c Global assessments by patients (left)
and investigator (right) in the post-marketing surveillance
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Global Assessment by Investigator The
efficacy of nadifloxacin in treatment of
bacterial skin infections was evaluated by
investigator on a 4-point scale as excellent
(complete remission of symptoms) for 239
(72.6%) patients, good (acceptable remission
of symptoms) in 46 (14.0%) patients, fair
(slight/incomplete remission of symptoms) in
42 (12.8%) patients and poor (unchanged/
aggravated) in 2 (0.6%) patients (Fig. 4c).
Safety Evaluation
Safety was assessed based on AEs following the
treatment. Study 1, 2 and 3 did not report any
AE as in the phase IV study, two AEs (burning
and itching) were reported, one in each
patient. Of the two AEs, itching persisted
whereas the burning improved at the time of
reporting. Of the two AEs, the causal
relationship of the AE in one patient was
‘‘Definitely Related’’ whereas in the other
patient the causal relationship of the AE was
‘‘Unrelated’’, as per the investigator/prescriber’s
assessment. No serious AEs were reported in
the studies.
DISCUSSION
The results of all the three comparative,
randomized clinical studies and the PMS
showed that nadifloxacin is well tolerated and
efficacious in the treatment of patients with
bacterial skin infections. There was a significant
reduction in mean severity scores for all the
symptoms of bacterial infections (including
erythema, crusting, exudation, swelling,
pruritus, pain, and tenderness) in the
nadifloxacin groups of all the three clinical
studies as compared with other study groups. In
all the studies (clinical and PMS), nadifloxacin
was rated as excellent (complete remission of
symptoms) on a 4-point scale by a significantly
higher number of patients as compared with
mupirocin, framycetin, and fusidic acid.
Investigators also rated the overall response to
the application of the study cream on a 4-point
scale as excellent (complete remission of
symptoms) in significantly higher number of
patients in the nadifloxacin groups. Minimal
AEs were reported.
Several antibiotics (fusidic acid, mupirocin,
framycetin and fluoroquinolones including
Table 2 Evaluation of symptoms before and after the treatment of bacterial skin infections with nadiﬂoxacin



















Erythema 87 (26.4) 114 (34.7) 27 (8.2) 101 (30.7) 9 (2.7) 0 (0.0) 12 (3.6) 1 (0.3) 0 (0.0)
Exudation 73 (22.2) 66 (20.1) 17 (5.2) 56 (17.0) 12 (3.6) 0 (0.0) 5 (1.5) 2 (0.6) 0 (0.0)
Swelling 81 (24.6) 81 (24.6) 20 (6.1) 66 (20.1) 14 (4.3) 0 (0.0) 10 (3.0) 2 (0.6) 0 (0.0)
Pruritus 66 (20.1) 43 (13.1) 29 (8.8) 58 (17.6) 7 (2.1) 1 (0.3) 8 (2.4) 0 (0.0) 0 (0.0)
Crusting 68 (20.7) 65 (19.8) 8 (2.4) 45 (13.7) 9 (2.7) 1 (0.3) 9 (2.7) 1 (0.3) 0 (0.0)
Pain 93 (28.3) 87 (26.4) 28 (8.5) 50 (15.2) 13 (4.0) 2 (0.6) 8 (2.4) 1 (0.3) 0 (0.0)
Tenderness 75 (22.8) 74 (22.5) 24 (7.3) 48 (14.6) 7 (2.1) 1 (0.3) 5 (1.5) 1 (0.3) 0 (0.0)
N number of patients
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ciprofloxacin, levofloxacin, gemifloxacin, and
moxifloxacin) are available for the treatment of
bacterial infections [3–5, 19, 20]. Nadifloxacin is
a new chemically synthesized fluoroquinolone
that has C-6 substituted with flouro group. The
presence of fluoro group enhances the anti-
bacterial activity of nadifloxacin probably by
improving its ability to bind the DNA gyrase
complex (2- to 17-fold) and cell penetration (1-
to 70-fold) as compared to quinolones with no
substitution [21, 22]. In vitro and clinical
studies have already proven the safety and
efficacy of nadifloxacin in the treatment of
acne vulgaris and suggested that nadifloxacin
could be used as an effective therapeutic agent
in treatment of other bacterial infections [14–
16, 23, 24]. All the studies conducted to date
(both in vitro and in vivo) have shown
nadifloxacin to be a superior treatment for
bacterial skin infections. Nadifloxacin has also
been reported to be effective against bacteria,
like MRSA, that have developed resistance to
other available anti-microbial [9, 13, 25].
Previous in vitro studies have assessed the
activity of nadifloxacin against bacterial skin
infection causing organisms. Nenoff et al. [10]
conducted an in vitro study that compared and
assessed the activity of nadifloxacin with
various other anti-bacterials including
oxacillin, flucloxacillin, ofloxacin,
erythromycin, cefotiam, clindamycin and
gentamicin against aerobic and anaerobic
Gram-positive bacteria including S. aureus,
coagulase-negative Staphylococci (CNS),
Streptococcus spp., Propionibacterium granulosum,
Propionibacterium acnes strains. The results
demonstrated nadifloxacin to be highly active
against all bacteria except some of the CNS
strains. Minimum inhibitory concentration
(MIC90 at which 90% of bacteria are inhibited)
of nadifloxacin was 0.1 lg/mL for S. aureus,
0.39 lg/mL for Propionibacterium spp., and
0.78 lg/mL for both Streptococcus spp. and
CNS, which was significantly less than MICs
for other test antibiotics. No resistant strains to
nadifloxacin were found in this study except for
some CNS strains in agreement with the study
by Vogt et al, who also reported the lowest
incidence of resistance of nadifloxacin against
the strains of CNS, S. aureus, P. acnes, and P.
granulosum [10, 26].
Another in vitro study, which compared the
activity of nadifloxacin with ciprofloxacin,
erythromycin and clindamycin against isolates
of P. acnes, S. epidermidis, and both methicillin-
susceptible and -resistant S. aureus (MSSA and
MRSA, respectively) taken from Spain, Hungary
and Germany showed that nadifloxacin
possesses better activity against strains of P.
acnes than other test antibiotics as the MIC50 (at
which 50% of bacteria are inhibited) and MIC90
values (range between 0.03 and 1 mg/L) for
nadifloxacin were lesser than MIC50 and MIC90
values of other test antibiotics. The study
observed that MSSA and MRSA strains were
more resistant to ciprofloxacin as compared to
nadifloxacin with exception of the MSSA
isolates from Spain in which 7.5% were
resistant to nadifloxacin [13]. Jacobs and
associates assessed the in vitro activity of
nadifloxacin against quinolone-susceptible and
-resistant S. aureus and S. epidermidis. The MIC of
nadifloxacin was less than all the other
currently available quinolones (clinafloxacin,
moxifloxacin, vancomycin, levofloxacin,
trovafloxacin, ciprofloxacin, teicoplanin)
which showed it to be the most potent
therapeutic agent against the tested
Staphylococci spp. (both quinolones susceptible
and resistant) [12].
There are limited clinical studies conducted
to assess the safety and efficacy of nadifloxacin
in treatment of bacterial skin infections.
Haustein and colleagues investigated the
244 Dermatol Ther (Heidelb) (2014) 4:233–248
efficacy and tolerability of nadifloxacin in
treatment of patients with bacterial infections
including impetigo contagiosa, folliculitis/
sycosis vulgaris, impetiginized dermatitis and
secondarily infected wounds. Statistically
significant reduction in the degree of
infections was observed and physicians rated
the therapeutic effect of nadifloxacin on a 4-
point scale as ‘very good’ in more patients
similar to that observed in our studies [17].
Resistance to anti-microbials is a menace in
treating bacterial infections. Drug export by
efflux pumps is a common mechanism for anti-
microbial drug resistance. Bacteria encode
several efflux pumps; extensive research is
reported on the NorA efflux pump. NorA
efflux pump is used by bacteria (such as S.
aureus) to pump out drugs leading to drug
resistance [27]. This inhibits the activity of
drugs on bacteria. Fluoroquinolones such as
ciprofloxacin, levofloxacin, and moxifloxacin
have shown resistance to both Gram-positive
(including Staphylococcus species) and Gram-
negative bacteria. However, nadifloxacin is not
influenced by over expression of the NorA efflux
pump on the bacterial cell membrane which
reduces the chances of development of
resistance [28, 29]. A previous study
determined that nadifloxacin acts independent
of NorA efflux pump, as MIC for NorA? S. aureus
was only one fold higher than that of NorA-
strain [12]. Several other studies demonstrated
nadifloxacin to have negligible or low resistance
against strains of S. aureus [10, 26, 30] and good
susceptibility to all bacteria that are resistant to
fluoroquinolones currently in use [10, 31, 32].
The authors’ studies were the first to
compare nadifloxacin with fusidic acid,
framycetin, and mupirocin for the treatment
of bacterial skin infection. The use of fusidic
acid, framycetin, and mupirocin in the
treatment of bacterial infections has been
investigated in several studies. A study, by
Gisby and co-workers, in mouse models with
skin wound infections compared the efficacy of
mupirocin with other antibiotics including
fusidic acid, neomycin–bacitracin,
erythromycin, cephalexin, benzylpenicillin,
methicillin and flucloxacillin used in the
treatment of primary and secondary bacterial
infections. In vitro results found that MIC value
of mupirocin for S. aureus was 0.12 lg/mL,
which is more than that reported by Nenoff
et al. in which the MIC value of nadifloxacin
was 0.1 lg/mL for S. aureus. This indicates that
nadifloxacin is a better option than mupirocin
and other comparator antibiotics used in this
study [4]. Another randomized clinical trial
reported that fusidic acid resistant strains of
MRSA were found in isolates of patients treated
with fusidic acid [33].
Spelman and his colleagues gathered in vitro
and clinical studies data to assess the efficacy
and safety of fusidic acid in treatment of
patients with bacterial infections. Though the
study demonstrated that fusidic acid is effective
against Staphylococci, Streptococci were resistant
to fusidic acid. However, nadifloxacin has
shown good efficacy against both Staphylococci
and Streptococci [10, 11].
Anti-bacterials currently used in the
treatment of bacterial skin infections such as
fusidic acid, mupirocin, and quinolones
including ciprofloxacin, levofloxacin,
moxifloxacin and gemifloxacin have been
reported to cause several AEs [14, 34–37].
However, nadifloxacin, a synthetic quinolone,
has been reported to cause minimal/negligible
AEs in the treatment of acne vulgaris. The data
on its AEs for use in the treatment of bacterial
skin infections are limited. Haustein et al.
reported AEs including itching, erythema and
inflammatory swelling in only three patients [7,
14, 17, 38]. The authors did not observe any AE
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in these clinical studies and the phase IV study
found only two AEs (burning and itching) and
of the two AEs, burning, improved at the time
of reporting. No serious AEs were reported in
the studies.
CONCLUSION
In the present study, the authors have reported
the results of three randomized clinical studies
and a PMS on the use of nadifloxacin in
treatment of bacterial skin infections in Indian
patients. They compared nadifloxacin with
other anti-bacterials used for treatment of
bacterial skin infections and showed
nadifloxacin to be safe and superior treatment
for bacterial skin diseases.
Future clinical trials of nadifloxacin in the
treatment of bacterial skin infections should be
conducted to assess long-term efficacy and
safety.
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